Participants sought for ‘superbug’ vaccine trial
FARGO — Researchers in Fargo are recruiting participants for clinical trials of a vaccine to prevent infections from a sometimes deadly “superbug” resistant to antibiotics.
The trial is open to those who are 50 or older and planning an upcoming hospitalization. Those who have had at least two hospital stays and have received oral or intravenous antibiotics in the past year also are eligible.
The vaccine aims to prevent infections from bacteria called Clostridium difficile, some strains of which have become resistant to antibiotics. The bacteria infect an estimated 500,000 Americans every year, resulting in more than 14,000 deaths.
The bacteria produce toxins that inflame the intestine, causing severe diarrhea that can persist in people with weak immune systems, including the elderly. Many of the infections are acquired in hospitals or other health care settings.
Dr. Paul Mariani, an infectious disease specialist at Sanford Health, is a local director in the national clinical trial, one of the first sites in the country to test the vaccine made by Sanofi Pasteur.
Because some strains of the Clostridium difficile are resistant to antibiotics, doctors are running out of treatments, Mariani said.
“We don’t have a huge armamentarium against this infection,” he said, adding that three main drugs are used.
A relatively new procedure, fecal micro biotic transfer, also is available and works in 94 percent of cases, although it is not a “first line” therapy.
“It works very well,” Mariani said, though the Food and Drug Administration still considers it experimental.
For more information about the vaccine, Cdiffense, go online to cdiffense.org. To see about enrolling in the study, call 701-234-2718.